We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.50 | -0.41% | 1,583.50 | 1,582.50 | 1,583.00 | 1,595.50 | 1,580.00 | 1,593.00 | 5,931,081 | 16:35:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.22 | 65.15B |
TIDMGSK
RNS Number : 8274Q
GlaxoSmithKline PLC
22 June 2015
Issued: 22 June 2015, London UK - LSE Announcement
Regulatory update on divestment of Nimenrix and Mencevax
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced it is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc).
The sale follows commitments given to the European Commission and other regulators in connection with the merger control clearances obtained for GSK's three-part transaction with Novartis AG, which completed on 2 March 2015. As part of the transaction, GSK acquired Novartis's vaccines business (excluding influenza vaccines) including the meningitis vaccines Menveo and Bexsero. In order to satisfy regulatory clearances as part of the transaction, GSK agreed to divest its legacy meningitis vaccines Nimenrix and Mencevax, which are sold outside the US and achieved combined global sales in 2014 of GBP34 million.
The agreementwith Pfizer Ireland Pharmaceuticals remains subject to final European Commission approval, other regulatory approvals and other customary closing conditions, which we hope to receive in the coming months. It is expected that the sale will be completed before the end of the year. The total consideration for the sale, including some deferred consideration, is EUR115 million (GBP82 million).
Pfizer Ireland Pharmaceuticals is deemed, under Listing Rule 11.1.4R, to be a related party of GSK as a result of holdings of the Pfizer group in ViiV Healthcare Limited.
The sale is a smaller related party transaction under Listing Rule 11.1.10R (1) and has been agreed following a confirmation from GSK's sponsor that the terms of the sale are fair and reasonable as far as GSK's shareholders are concerned.
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GSK enquiries: UK Media enquiries: David Mawdsley +44 (0) 20 (London) 8047 5502 Simon Steel +44 (0) 20 (London) 8047 5502 David Daley +44 (0) 20 (London) 8047 5502 Catherine +44 (0) 20 (London) Hartley 8047 5502 Sarah Spencer +44 (0) 20 (London) 8047 5502 Claire Brough +44 (0) 20 (London) 8047 5502 US Media enquiries: Sarah Alspach +1 202 715 (Washington, 1048 DC) Mary Anne +1 919 483 (North Rhyne 0492 Carolina) Melinda Stubbee +1 919 483 (North 2510 Carolina) Jenni Ligday +1 202 715 (Washington, 1049 DC) Karen Hagens +1 919 483 (North 2863 Carolina) Gwynne Oosterbaan +1 215 751 (Philadelphia) 7468 Analyst/Investor Ziba Shamsi +44 (0) 20 (London) enquiries: 8047 5543 Tom Curry + 1 215 751 (Philadelphia) 5419 Gary Davies +44 (0) 20 (London) 8047 5503 James Dodwell +44 (0) 20 (London) 8047 2406 Jeff McLaughlin +1 215 751 (Philadelphia) 7002 Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014. Registered in England & Wales: No. 3888792 Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUPUQUPAGGP
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions